Loading...

KALA KALA BIO INC Operational Disruptions 8-K Filing

KL B

KL

KALA BIO INC

(KALA)

2023 8-K

Show Summary

Summary

Product Expansion

Executive Retention

Financial Results

CEO Resignation

Financial Results

Director Resignation

Earnings Reports

Securities Purchase Agreement

Annual Meeting Results

Financial Results Announcement

Financial Results Announcement

Securities Purchase Agreement

Presentation and Clinical T...

Securities Purchase Agreement

Financial Results Announcement

Financial Results

Departure of Directors or C...

Financial Results Announcement

Meeting Results

Clinical Trial Results

Financial Results Announcement

Open Market Sale Agreement

Listing Transfer Approval

External Links:

Kala Pharmaceuticals announced positive safety data from the first cohort of a clinical trial for the treatment of corneal epithelial defect.

AI Assistant

KALA BIO INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.